Dianthus Therapeutics, Inc.
DNTHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. With a market capitalization of $6.05B, it sits in mid-cap territory. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Market Cap
$6.05B
Beta
0.06
P/E (TTM)
—
P/E (Fwd)
-23.42
EPS (TTM)
$-4.24
EPS (Fwd)
$-4.62
ROE
-26.1%
ROA
-17.7%
Cash
$886.8M
Total Debt
$1.3M
Free CF
-$92.2M
52W Change
203.9%
Annual Financials
Cash vs Debt
Where DNTH stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, DNTH finished 34.02% above its 150-day moving average ($82.90) and 53.43% above its 200-day moving average ($72.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DNTH overbought or oversold?
At the August 24, 2026 close, DNTH's RSI(14) was 56.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Dianthus Therapeutics, Inc. holds $886.8M in cash against $1.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$92.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $6.4M (2022) to $2.0M (2025), a 68% decline worth watching.
With a beta below 0.7, Dianthus Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DNTH.